Tony Hagen

The signing of the Medical Access and CHIP Reauthorization Act of 2015 ends the yearly nightmare of congressional budget wrangling associated with the Sustainable Growth Rate formula.

Going bankrupt is high on the list of worries for 37.1% of cancer patients who participated in a recently published survey by the Washing- ton, DC-based Cancer Support Community, an international nonprofit.

Earlier diagnosis, longer treatment durations, and increased effectiveness of treatments helped to boost spending on cancer medicines to the $100 billion threshold in 2014, a rise of 10.3% for the year, and up markedly from $75 billion five years earlier.

The field of prostate cancer vaccines remains an area of active exploration, with clinical trials into sipuleucel-T continuing even amid a corporate restructuring and a phase III study into PROSTVAC reaching full enrollment.

Frustration is mounting with a federal program that was originally designed to allow hospitals that care for underserved people to purchase outpatient drugs at discounted prices.

For Gladys Rodriguez, MD, a practicing oncologist for 24 years, the daily schedule is filled with calls to payers and hours spent at the computer typing up electronic health records.

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients.

The American Society of Hematology is calling for the creation of a new clinical hematology specialty that would be based in a medical center or health system and would focus primarily on patients with benign blood disorders, while also helping to manage genomic testing and pathways-centered care.

Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.

A bill to repeal the SGR formula garnered critical support with a vote by the House of Representatives.

Leaders in Congress today reached a bipartisan, bicameral deal to permanently repeal and replace Medicare's sustainable growth-rate formula for paying physicians.

Patients with cancer are living longer thanks to new treatments, but the US oncology care system is burdened by growing administrative responsibilities, difficulties obtaining payment, and runaway costs.

A new report has called for broad changes in the way drugs are priced in the United States, saying the law of supply and demand is not doing an effective job of bringing the cost of cancer drugs down to a level comparable with other countries.

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.

The Centers for Medicare & Medicaid Services has announced the launch of a "Next Generation Accountable Care Organization Model," designed to increase savings on healthcare spending while improving medical care.

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

The COA has weighed in on a new system of higher value performance for oncologists, saying it is a step in the right direction but needs to be supported by broader reforms.

The American Board of Internal Medicine (ABIM) is making substantial changes to its Maintenance of Certification Program (MOC) for internists and subspecialists.

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.